. | eGFR (ml/min per 1.73 m^{2}). | . | . | . | |||
---|---|---|---|---|---|---|---|

. | ≥90 . | 60–89 . | 30–59 . | 15–29 . | |||

Cardiovascular end points | |||||||

No albuminuria [HR (95% CI), P value] | 1.00 (referent) | 1.00 (0.59–1.72), P = 0.991 | 3.05 (1.51–6.15), P = 0.002 | Not enough subjects | |||

Albuminuria [HR (95% CI), P value] | 1.85 (1.07–3.18), P = 0.03 | 1.89 (1.13–3.16), P = 0.016 | 1.35 (0.74–2.49), P = 0.33 | 5.46 (2.78–10.7), P < 0.001 | |||

Renal end points | |||||||

No albuminuria [HR (95% CI), P value] | 1.00 (referent) | 0.83 (0.35–1.96), P = 0.67 | 0.82 (0.12–6.22), P = 0.85 | Not enough subjects | |||

Albuminuria [HR (95% CI), P value] | 2.62 (1.31–5.26), P = 0.007 | 4.13 (2.19–7.78), P < 0.001 | 10.27 (5.52–19.11), P < 0.001 | 90.29 (45.80–178.03), P < 0.001 | |||

Composite end points^{*} | |||||||

No albuminuria [HR (95% CI), P value] | 1.00 (referent) | 1.21 (0.80–1.84), P = 0.36 | 2.98 (1.57–5.64), P = 0.001 | Not enough subjects | |||

Albuminuria [HR (95% CI), P value] | 2.34 (1.58–3.50), P < 0.001 | 2.43 (1.64–3.59), P < 0.001 | 3.15 (2.06–4.82), P < 0.001 | 16.2 (10.0–26.0), P < 0.001 |

. | eGFR (ml/min per 1.73 m^{2}). | . | . | . | |||
---|---|---|---|---|---|---|---|

. | ≥90 . | 60–89 . | 30–59 . | 15–29 . | |||

Cardiovascular end points | |||||||

No albuminuria [HR (95% CI), P value] | 1.00 (referent) | 1.00 (0.59–1.72), P = 0.991 | 3.05 (1.51–6.15), P = 0.002 | Not enough subjects | |||

Albuminuria [HR (95% CI), P value] | 1.85 (1.07–3.18), P = 0.03 | 1.89 (1.13–3.16), P = 0.016 | 1.35 (0.74–2.49), P = 0.33 | 5.46 (2.78–10.7), P < 0.001 | |||

Renal end points | |||||||

No albuminuria [HR (95% CI), P value] | 1.00 (referent) | 0.83 (0.35–1.96), P = 0.67 | 0.82 (0.12–6.22), P = 0.85 | Not enough subjects | |||

Albuminuria [HR (95% CI), P value] | 2.62 (1.31–5.26), P = 0.007 | 4.13 (2.19–7.78), P < 0.001 | 10.27 (5.52–19.11), P < 0.001 | 90.29 (45.80–178.03), P < 0.001 | |||

Composite end points^{*} | |||||||

No albuminuria [HR (95% CI), P value] | 1.00 (referent) | 1.21 (0.80–1.84), P = 0.36 | 2.98 (1.57–5.64), P = 0.001 | Not enough subjects | |||

Albuminuria [HR (95% CI), P value] | 2.34 (1.58–3.50), P < 0.001 | 2.43 (1.64–3.59), P < 0.001 | 3.15 (2.06–4.82), P < 0.001 | 16.2 (10.0–26.0), P < 0.001 |

*

Composite end points included all-cause mortality and cardiovascular and renal end points. Covariates included age, sex, duration of diabetes, smoking, BMI, systolic blood pressure, HDL and LDL cholesterol, triglycerides, A1C, RAAS inhibition and prevalent retinopathy.

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.